

September 10, 2025

Perseus Proteomics, Inc.

President & CEO: Takuya Yokokawa

e-mail: [ir@ppmx.com](mailto:ir@ppmx.com)

**Notice of Selection for JST A-STEP Program – Industry-Academia  
Collaboration Stage II (Full-Scale Phase)**

Perseus Proteomics Inc. (President & CEO: Takuya Yokokawa, TSE Growth Market: Code 4882) is pleased to announce its selection for the FY2025 “Research Acceleration Program for Optimal Deployment—A-STEP, Industry-Academia Collaboration Stage II (Full-Scale Phase)” by the Japan Science and Technology Agency (JST), together with the following collaborators: Yamagata University, Osaka Metropolitan University, Tokyo University of Agriculture and Technology, and Tohoku University.

Please note that this event will have no impact on the company’s financial results for the current fiscal period.

**Project Title:**

Development Platform for Fully Natural IgG-Type Bispecific Antibody Drugs

**Research Development Period:**

October 1, 2025 – March 31, 2030

**Project Overview:**

This project aims to establish manufacturing technologies for highly functional, fully natural IgG-type bispecific antibodies, by combining next-generation biopharmaceutical design technologies contributed by each university group. Bispecific antibodies can simultaneously bind to two or more distinct antigens, providing the potential for advanced therapeutic effects. We intend to establish a comprehensive platform for screening and industrial-scale manufacturing of antibody molecules composed exclusively of natural sequences. This platform will be implemented in society via licensing, commercialization as screening kits, and contract services.

**Reference:**

For more details about the A-STEP, please refer to the JST website:

<https://www.jst.go.jp/a-step/>

END